Pregabalin Capsule
Product Images NDC 72658-0809

24 FDA label images from Eskayef Pharmaceuticals Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 24 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72658-0809). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eskayef Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula (Formula)

Formula (Formula)
Chemical formula image illustrating the calculation of Creatinine Clearance (CLCr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. It depicts a pharmacokinetic expression rather than a molecular structure.*
FDA Label Image

Structure (Structure1)

Structure (Structure1)
Chemical structure diagram of Pregabalin, showing its molecular framework including an amino group and a carboxylic acid group.*
FDA Label Image

Figure 1 (Figure01)

Figure 1 (Figure01)
A line graph depicting percent of patients improved versus percent improvement in pain from baseline. It compares four treatments: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The vertical axis shows percent of patients improved from 0 to 100%, and the horizontal axis shows percent improvement in pain from baseline, ranging from over 0% to 100%. Four distinct trend lines represent the different treatment groups.*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It displays two curves: one for Pregabalin 100 mg taken three times a day and another for placebo, illustrating the difference in pain improvement over a range of percentages.*
FDA Label Image

Figure 3 (Figure03)

Figure 3 (Figure03)
A line graph illustrating percent improvement in pain from baseline along the x-axis and percent of patients improved along the y-axis. The graph compares the effectiveness of Pregabalin capsules at 75 mg, 160 mg, and 300 mg taken two times a day versus placebo, showing higher doses generally associated with greater patient improvement percentages.*
FDA Label Image

Figure 4 (Figure4)

Figure 4 (Figure4)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares three groups: patients taking Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and a placebo group. The graph includes vertical lines at approximately 30% and 50% improvement markers.*
FDA Label Image

Figure 5 (Figure5)

Figure 5 (Figure5)
A line graph comparing the percent improvement in pain from baseline with the percent of patients improved for Pregabalin 50 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The x-axis shows percent improvement in pain from 0 to 100%, and the y-axis shows the percent of patients improved from 0 to 100%. Two vertical lines mark around 30% and 50% improvement thresholds.*
FDA Label Image

Figure 6 (Figure6)

Figure 6 (Figure6)
A bar graph showing responder rates (%) for Pregabalin at different dosages in two studies labeled Study E1 and Study E3. The x-axis represents treatment groups including placebo, BID (twice daily), and TID (three times daily) dosages, while the y-axis shows responder rates from 0% to 60%. Statistical significance compared to placebo is noted.*
FDA Label Image

Figure 7 (Figure7)

Figure 7 (Figure7)
A line graph showing the median percentage reduction in seizures from baseline versus dose in mg/day for Pregabalin from multiple studies (E1, E2, E3) with different dosing schedules (BID, TID). The chart highlights statistical significance with p-values at various dose points for placebo and active treatment groups.*
FDA Label Image

Figure 8 (Figure8)

Figure 8 (Figure8)
A bar graph showing responder rates as percentages for three groups: Placebo (22.6%, n=93), 2.5 mg/kg/day (29.1%, n=103), and 10 mg/kg/day (40.6%, n=96). The vertical axis represents responder rate percentages, and the horizontal axis lists the treatment groups with sample sizes.*
FDA Label Image

Figure 9 (Figure9)

Figure 9 (Figure9)
A line chart illustrating the percent improvement in pain from baseline versus the percent of patients improved. It compares patient responses to Pregabalin at daily doses of 300 mg, 450 mg, and 600 mg, as well as a placebo group, showing varying degrees of pain improvement among the groups.*
FDA Label Image

Figure 10 (Figure10)

Figure 10 (Figure10)
A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (loss to response) over 180 days for Pregabalin versus placebo. The x-axis represents days, and the y-axis shows the estimated percentage of subjects without LTR. The Pregabalin group shows a consistently higher percentage without LTR than the placebo group throughout the study period.*
FDA Label Image

Figure 11 (Figure11)

Figure 11 (Figure11)
A line graph showing the percent of subjects improved over time from baseline to week 12. The x-axis represents the percent improvement from baseline to week 12 BOCF, ranging from 0 to 100 percent. The y-axis indicates the percent of subjects improved, ranging from 0 to 100 percent. Two lines compare Pregabalin (solid line) and placebo (dashed line) treatments, with Pregabalin showing a higher percent of subjects improved throughout the range.*
FDA Label Image

Figure 12 (Figure12)

Figure 12 (Figure12)
A line graph comparing the percentage of subjects improved over time between Pregabalin and placebo groups. The x-axis represents the percent improved from baseline to week 16 BOCF, and the y-axis shows the percent of subjects improved. The Pregabalin group shows consistently higher improvement compared to placebo.*
FDA Label Image
FDA Label Image

Logo (Logo1)

Logo (Logo1)
PREGABALIN capsules by Eskayef Pharmaceuticals Limited. The packaging displays the brand name prominently and indicates it contains capsules for oral use. Dosage strengths are not visible on the carton. The labeler logo, Eskayef Pharmaceuticals Limited, is also present on the box.*
FDA Label Image

Pregablin-25-60s-v2 (Pregablin 25 60s V2)

Pregablin-25-60s-v2 (Pregablin 25 60s V2)
Label for Pregabalin Capsules 25 mg by Eskayef Pharmaceuticals Limited. The label includes storage instructions (20° to 25°C, excursions allowed), dosing directions referencing prescribing info, and states each capsule contains 25 mg pregabalin USP. Package contains 60 capsules and includes barcodes and manufacturing information for Eskayef Pharmaceuticals in Bangladesh.*
FDA Label Image

Pregabalin-50-60s-v2 (Pregablin 50 60s V2)

Pregabalin-50-60s-v2 (Pregablin 50 60s V2)
Label for Pregabalin Capsules 50 mg by Eskayef Pharmaceuticals Limited. The label indicates oral capsules in a 60 count package with storage instructions (20° to 25°C), dispensing instructions, and a barcode. Contains prescription-only information with manufacturer details in Bangladesh.*
FDA Label Image

Pregabalin-75-60s-v2 (Pregablin 75 60s V2)

Pregabalin-75-60s-v2 (Pregablin 75 60s V2)
Label for Pregabalin Capsules 75 mg, oral dosage form, containing 60 capsules. The label notes storage instructions, pharmacist dispensing directions, and manufacturer details as Eskayef Pharmaceuticals Limited in Bangladesh. The NDC is 72658-0810-1 and the product is identified as prescription only from SK+F.*
FDA Label Image

Pregablin-100-60s-v2 (Pregablin 100 60s V2)

Pregablin-100-60s-v2 (Pregablin 100 60s V2)
Label for Pregabalin Capsules 100 mg by Eskayef Pharmaceuticals Limited, displaying storage instructions at controlled room temperature, packaging of 60 capsules, and a note to dispense the accompanying Medication Guide. The label includes NDC 72658-0811-1 and manufacturer information in Bangladesh.*
FDA Label Image

Pregablin-150-60s-v2 (Pregablin 150 60s V2)

Pregablin-150-60s-v2 (Pregablin 150 60s V2)
Label for Pregabalin Capsules 150 mg, oral dosage form, manufactured by Eskayef Pharmaceuticals Limited. The label states storage instructions, dispensing guidance, and contains barcodes. The package contains 60 capsules and is marked for prescription use only.*
FDA Label Image

Pregablin-200-60s-v2 (Pregablin 200 60s V2)

Pregablin-200-60s-v2 (Pregablin 200 60s V2)
Label for Pregabalin Capsules 200 mg oral dosage form by Eskayef Pharmaceuticals Limited. The label includes storage instructions, pharmacist dispensing notes, and states the package contains 60 capsules. Registration details such as NDC 72658-0849-1 and manufacturer address in Bangladesh are also displayed. The label features a barcode and a 2D barcode placeholder area.*
FDA Label Image

Pregablin-225-60s-v2 (Pregablin 225 60s V2)

Pregablin-225-60s-v2 (Pregablin 225 60s V2)
Label for Pregabalin Capsules 225 mg by Eskayef Pharmaceuticals Limited. The label indicates storage instructions, prescription-only status, and a quantity of 60 capsules. Manufacturer address and a barcode are visible. The label includes a pharmacist note to dispense the medication guide with the product.*
FDA Label Image

Pregablin-300-60s-v2 (Pregablin 300 60s V2)

Pregablin-300-60s-v2 (Pregablin 300 60s V2)
Label for Pregabalin Capsules 300 mg by Eskayef Pharmaceuticals Limited shows dosage strength prominently on a white background with a pink highlight. The label states storage conditions, container type, quantity of 60 capsules, and includes manufacturer address in Bangladesh. Barcode and Rx only status are also visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.